Literature DB >> 34514036

Progressive Encephalomyelitis with Rigidity and Myoclonus and Myasthenia Gravis Comorbid Status with Thymoma.

Takashi Ogawa1,2, Kotaro Ogaki1,3, Kensuke Daida1,2, Takayasu Nishimaki1,4, Maya Ando1, Sumihiro Kawajiri1,5, Ryo Wada6, Kazuyuki Noda1, Nobutaka Hattori2, Yasuyuki Okuma1.   

Abstract

Entities:  

Keywords:  anti‐glycine receptor; myasthenia gravis; progressive encephalomyelitis with rigidity and myoclonus; systemic myoclonus and spasms; thymoma

Year:  2021        PMID： 34514036      PMCID： PMC8414492          DOI： 10.1002/mdc3.13293

Source DB:  PubMed          Journal:  Mov Disord Clin Pract        ISSN： 2330-1619


× No keyword cloud information.
  5 in total

Review 1.  Myasthenia Gravis.

Authors:  Nils E Gilhus
Journal:  N Engl J Med       Date:  2016-12-29       Impact factor: 91.245

Review 2.  Autoimmune retinopathy: a review and summary.

Authors:  John R Heckenlively; Henry A Ferreyra
Journal:  Semin Immunopathol       Date:  2008-04-12       Impact factor: 9.623

3.  Glycine receptor antibodies in PERM and related syndromes: characteristics, clinical features and outcomes.

Authors:  Alexander Carvajal-González; M Isabel Leite; Patrick Waters; Mark Woodhall; Ester Coutinho; Bettina Balint; Bethan Lang; Philippa Pettingill; Aisling Carr; Una-Marie Sheerin; Rayomand Press; Raomand Press; Michael P Lunn; Ming Lim; Paul Maddison; H-M Meinck; Wim Vandenberghe; Angela Vincent
Journal:  Brain       Date:  2014-06-20       Impact factor: 13.501

4.  Coexistence of Autoimmune Encephalitis and Other Systemic Autoimmune Diseases.

Authors:  Jing Zhao; Cancan Wang; Xiaolu Xu; Yuanxing Zhang; Haitao Ren; Zhixia Ren; Gai Li; Jiewen Zhang; Hongzhi Guan
Journal:  Front Neurol       Date:  2019-10-31       Impact factor: 4.003

5.  Thymoma-associated Progressive Encephalomyelitis with Rigidity and Myoclonus (PERM) with Myasthenia Gravis.

Authors:  Satoshi Morise; Masataka Nakamura; Jun-Ichi Morita; Kousuke Miyake; Takenobu Kunieda; Satoshi Kaneko; Hirofumi Kusaka
Journal:  Intern Med       Date:  2017-07-01       Impact factor: 1.271
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.